Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07261150 · ClinicalTrials.gov registry record · Phase 3
Histoplasmosis Induction and Consolidation Therapy Factorial Randomized Clinical Trial (Histo-FACT)
A Phase 3 study, sponsored by University of Minnesota.
- Not yet
- Registry status
- Phase 3
- Development phase
- 664
- Enrollment target
NCT07261150: Clinical Trial Phase 3 study, sponsored by University of Minnesota.
NCT07261150 is a Phase 3 study that has not yet begun recruiting, run by University of Minnesota. The registered enrollment target is 664 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (14% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07261150, a Phase 3 study, has not yet begun recruiting, sponsored by University of Minnesota.
- NOT YET RECRUITING
- Registry status
- Phase 3
- Development phase
- 664 participants
- Enrollment target
Study Summary
The purpose of the study is threefold: 1. Assess the safety and efficacy of a single high-dose intravenous (LAmB 10mg/kg) compared to the SOC daily dosing (3mg/kg) of the same medication for induction therapy in moderate to severe histoplasmosis. 2. Assess the safety and efficacy of oral posaconazole 300mg delayed-release tablets three times daily for two days then once daily for consolidation therapy compared to SOC oral itraconazole 200 mg capsules three times daily for three days then twice daily in moderate to severe histoplasmosis 3. Assess the safety and efficacy of 6 months of consolidation therapy compared to the SOC 12 months of consolidation therapy in persons with HIV on appropriate antiretroviral therapy.
Interventions
- DRUG Posaconazole
- DRUG LAmB B
- DRUG World Health Organization (WHO)-recommended SOC
- DRUG WHO-recommended SOC Itraconazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 664 participants |
| Start Date | 2026-09-15 |
| Est. Completion | 2030-12-31 |
| Phase | Phase 3 |
What is known before NCT07261150 opens enrollment
NCT07261150 is an interventional study that assigns participants to a tested intervention. The registered 664 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (14% lower).
The record links to 0 conditions, and to 4 interventions - of which Posaconazole is the first listed.
NCT07261150 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07261150 about?
NCT07261150 is a clinical study titled "Histoplasmosis Induction and Consolidation Therapy Factorial Randomized Clinical Trial (Histo-FACT)". The purpose of the study is threefold: 1. Assess the safety and efficacy of a single high-dose intravenous (LAmB 10mg/kg) compared to the SOC daily dosing (3mg/kg) of the same medication for induction therapy in moderate to severe histoplasmosis. 2. Assess the safety and efficacy of oral posaconazo...
What is the current status of trial NCT07261150?
This trial is currently not yet recruiting. It is a Phase 3 study. The enrollment target is 664 participants. The study started on 2026-09-15. Estimated completion is 2030-12-31.
What interventions are being tested in trial NCT07261150?
The interventions under investigation include: Posaconazole (DRUG), LAmB B (DRUG), World Health Organization (WHO)-recommended SOC (DRUG), WHO-recommended SOC Itraconazole (DRUG).
Who is sponsoring clinical trial NCT07261150?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07261150's enrollment target sits among peer trials
664 553rd of 2000 higher than 1,448 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06607341 · 664 participants · NA
Community Engagement Alliance Against Disparities
- NCT04064060 · 665 participants · Phase 3
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
- NCT07164443 · 663 participants · Phase 3
A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
- NCT06328647 · 666 participants · NA
Quantra Point-of-Care Hemostasis Monitoring
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI